Literature DB >> 11602675

Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation.

M R Brandt1, M S Furness, K C Rice, B D Fischer, S S Negus.   

Abstract

Tolerance and dependence after acute or chronic administration of the selective delta-opioid agonist SNC80 were assessed in rhesus monkeys (Macaca mulatta) responding under a schedule of food presentation. SNC80 dose dependently decreased response rates. These effects waned after 5 h. When administered as an acute 24-h pretreatment, SNC80 (1.0-10.0 mg/kg) produced tolerance as evidenced by dose-dependent rightward shifts in the SNC80 dose-effect curve. Pretreatments of 3.2 or 10.0 mg/kg SNC80 increased the SNC80 ED50 by 4- or 25-fold, respectively. Tolerance to acute SNC80 was also time-dependent as evidenced by increased ED50 values when administered as a 5-h (14-fold), 24-h (25-fold), or 3-day (11-fold) pretreatment. The SNC80 dose-effect curve was similar to control after a 7-day pretreatment. The selective delta-antagonist naltrindole (1.0 mg/kg) partially blocked tolerance to acute SNC80. Chronic SNC80 (1.0-10.0 mg/kg/day) also produced dose-dependent rightward shifts in the SNC80 dose-effect curve. Chronic SNC80 was more effective than acute SNC80 in producing tolerance. Moreover, tolerance to chronic SNC80 waned more slowly than to acute SNC80. Acute or chronic SNC80 (10.0 mg/kg/day) also produced cross-tolerance to the rate-decreasing effects of other delta-agonists (SNC162 and SNC243A) but not to mu- (morphine) or kappa (U-50,488)-agonists. Changes in response rates or behavioral signs of withdrawal were not observed after the administration of opioid antagonists (i.e., naltrindole or naltrexone) in monkeys treated with SNC80. These data suggest that a pharmacologically selective tolerance develops to delta-agonists after both acute and chronic administration of SNC80 with little or no dependence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602675

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats.

Authors:  David A Thorn; Yanan Zhang; Jun-Xu Li
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

2.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

3.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

4.  The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors.

Authors:  Matthew D Metcalf; Ajay S Yekkirala; Michael D Powers; Kelley F Kitto; Carolyn A Fairbanks; George L Wilcox; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2012-05-22       Impact factor: 4.418

Review 5.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

6.  Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Nancy K Mello; Kenner C Rice; John E Folk; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2006-07-05       Impact factor: 4.432

7.  Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

8.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 10.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.